ArticleNature medicine2024
Ultrasensitive plasma-based monitoring of tumor burden using machine-learning-guided signal enrichment.
Abstract read
In one paragraph
Article in Nature medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 98 papers, 3 of them syntheses that pooled it.
0numbers the graph read from it
0cells of the map it votes in
98citing papers in PubMed, 3 pooled it
–field-weighted citation impact
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
98 citing papers in PubMed, 3 syntheses or guidelines pooled it.
- Blood-Based Circulating Tumor DNA Assays for Early Colorectal Cancer Detection: A Systematic Review of Performance in Asymptomatic Screening Populations.International journal of cancer · 2026Pooled it
- Global research trends and focus on biomarkers in lung cancer immunotherapy: a comprehensive bibliometric insight and visualization analysis (2001-2025).Frontiers in immunology · 2026Pooled it
- Research trends and hotspots of circulating tumor DNA in colorectal cancer: a bibliometric study.Frontiers in oncology · 2025Pooled it
- A streamlined hybrid-capture and genome-wide multi-omic platform for highly sensitive ctDNA minimal residual disease monitoring.The journal of liquid biopsy · 2026Article
- Exercise therapy in cancer prevention and treatment.Nature reviews. Clinical oncology · 2026Review
- A guide to understanding tumour evolution through the lens of population genetics.Nature reviews. Cancer · 2026Review
- Molecular sampling limits of ctDNA detection in clinical plasma samples.The journal of liquid biopsy · 2026Article
- Advancing the applications of liquid biopsies in oncology.Nature reviews. Genetics · 2026Review
- Circulating Tumor DNA as a Biomarker for Melanoma Prognosis and Therapy.American journal of clinical dermatology · 2026Review
- Circulating tumor DNA-based minimal residual disease-guided adjuvant therapy in solid tumors: Current evidence, clinical trial frameworks, and future directions.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2026Article
- The role of serologic biomarkers "liquid biopsy" in the fight against breast cancer: From biological foundations to clinical impact.iScience · 2026Review
- Methyltransferase-assisted single duplex sequencing for detecting circulating tumor DNA.EMBO molecular medicine · 2026Article
- Circulating Tumor DNA for Minimal Residual Disease Detection and Recurrence Prediction in Upper Gastrointestinal Cancers: A Scoping Review.Journal of clinical medicine · 2026Review
- An alignment-free strategy for circulating tumor DNA detection and tumor fraction estimation from whole-genome sequencing data.PLoS computational biology · 2026Article
- [Clinical Frontiers and Applications Progress of ctDNA in Precision Treatment of Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2026Review
- A scalable deep-learning framework for cancer detection using cell-free DNA shallow whole-genome sequencing.Science advances · 2026Article
- The sleeping threat: targeting cancer dormancy to transform metastasis therapy.Nature reviews. Cancer · 2026Review
- Review
- Article
- Tumor-naïve ctDNA detection with deep learning-enhanced error suppression for sensitive mutation calling.Genome medicine · 2026Article
38 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
61 authors.
Adam J Widman *New York Genome Center, New York, NY, USA. widmana@mskcc.org.ORCID 0000-0001-7953-0677
Minita Shah *New York Genome Center, New York, NY, USA.
Amanda Frydendahl *Department of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0001-9552-5421
Daniel Halmos *New York Genome Center, New York, NY, USA.
Cole C KhamneiNew York Genome Center, New York, NY, USA.
Nadia ØgaardDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Srinivas RajagopalanNew York Genome Center, New York, NY, USA.
Anushri AroraNew York Genome Center, New York, NY, USA.
Aditya DeshpandeNew York Genome Center, New York, NY, USA.
William F HooperNew York Genome Center, New York, NY, USA.
Jean QuentinNew York Genome Center, New York, NY, USA.
Jake BassNew York Genome Center, New York, NY, USA.ORCID 0000-0001-8703-8877
Mingxuan ZhangNew York Genome Center, New York, NY, USA.
Theophile LanganayNew York Genome Center, New York, NY, USA.
Laura AndersenDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID 0009-0001-0223-3401
Zoe SteinsnyderNew York Genome Center, New York, NY, USA.
Will LiaoNew York Genome Center, New York, NY, USA.ORCID 0000-0001-7574-4694
Mads Heilskov RasmussenDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0001-5723-6303
Tenna Vesterman HenriksenDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.
Sarah Østrup JensenDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0001-6044-3362
Jesper NorsDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-9104-7263
Christina TherkildsenGastro Unit, Copenhagen University Hospital, Amager - Hvidovre Hospital, Hvidovre, Denmark.ORCID 0000-0002-2833-6986
Jesus SoteloNew York Genome Center, New York, NY, USA.
Ryan BrandNew York Genome Center, New York, NY, USA.ORCID 0000-0001-6412-6647
Joshua S SchiffmanNew York Genome Center, New York, NY, USA.ORCID 0000-0002-1028-1438
Ronak H ShahMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-9042-6213
Alexandre Pellan ChengNew York Genome Center, New York, NY, USA.ORCID 0000-0002-3667-0992
Colleen MaherMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-1117-9272
Lavinia SpainCancer Dynamics Laboratory, The Francis Crick Institute, London, UK.
Kate KrauseMass General Cancer Center, Massachusetts General Hospital, Boston, MA, USA.
Dennie T FrederickMass General Cancer Center, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0003-3355-5267
Wendie den BrokDepartment of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
Caroline LohrischDepartment of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
Tamara ShenkierDepartment of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
Christine SimmonsDepartment of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
Diego VillaDepartment of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.ORCID 0000-0002-4625-3009
Andrew J MungallMichael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.ORCID 0000-0002-0905-2742
Richard MooreMichael Smith Genome Sciences Centre, Vancouver, British Columbia, Canada.
Elena ZaikovaDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.ORCID 0000-0002-2422-3108
Viviana CerdaDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
Esther KongDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.ORCID 0000-0002-1315-4311
Daniel LaiDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.ORCID 0000-0001-9203-6323
Murtaza S MalbariWeill Cornell Medicine, New York, NY, USA.
Melissa MartonNew York Genome Center, New York, NY, USA.
Dina ManaaNew York Genome Center, New York, NY, USA.
Lara WinterkornNew York Genome Center, New York, NY, USA.
Karen GelmonDepartment of Medical Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.
Margaret K CallahanMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-9087-0012
Genevieve BolandMass General Cancer Center, Massachusetts General Hospital, Boston, MA, USA.ORCID 0000-0002-7522-6173
Catherine PotenskiNew York Genome Center, New York, NY, USA.
Jedd D WolchokMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0001-6718-2222
Ashish SaxenaWeill Cornell Medicine, New York, NY, USA.
Samra TurajlicCancer Dynamics Laboratory, The Francis Crick Institute, London, UK.ORCID 0000-0001-8846-136X
Marcin ImielinskiNew York Genome Center, New York, NY, USA.ORCID 0000-0002-2211-4741
Michael F BergerMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0003-3882-5000
Sam AparicioDepartment of Molecular Oncology, BC Cancer Agency, Vancouver, British Columbia, Canada.ORCID 0000-0002-0487-9599
Nasser K AltorkiWeill Cornell Medicine, New York, NY, USA.ORCID 0000-0001-9754-9945
Michael A PostowMemorial Sloan Kettering Cancer Center, New York, NY, USA.ORCID 0000-0002-3367-7961
Nicolas RobineNew York Genome Center, New York, NY, USA.ORCID 0000-0001-5698-8183
Claus Lindbjerg AndersenDepartment of Molecular Medicine, Aarhus University Hospital, Aarhus, Denmark.ORCID 0000-0002-7406-2103
Dan A LandauNew York Genome Center, New York, NY, USA. dlandau@nygenome.org.ORCID 0000-0003-2346-9541
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MTraining Grant in Molecular Imaging Research (MGH/HMS)T32CA079443 · NCI · MASSACHUSETTS GENERAL HOSPITAL · PI WEISSLEDER, MD, PHD, RALPH · 2000 to 2025
$10.1MGenome-wide mutational integration for ultra-sensitive plasma tumor burden monitoring in immunotherapyR01CA266619 · NCI · WEILL MEDICAL COLL OF CORNELL UNIV · PI Dan Landau, Nicolas Robine · 2022 to 2026
$3.2MAdvanced machine learning to empower ultra-sensitive liquid biopsy in melanoma and non-small cell lung cancerK08CA263301 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI Adam Widman · 2023 to 2026
$1.2MDeciphering Clonal Evolution in Hereditary Renal Cell CarcinomasU01CA247439 · NCI · FRANCIS CRICK INSTITUTE, LTD · PI TURAJLIC, SAMRA · 2020 to 2024
$1.1MCancer Research UK 29911Cancer Research UK CC2044Melanoma Research Alliance (MRA) 1039927NCI NIH HHS K08 CA263301NCI NIH HHS P30 CA008748NCI NIH HHS R01 CA266619NCI NIH HHS T32 CA079443NCI NIH HHS U01 CA247439U.S. Department of Health & Human Services | NIH | National Cancer Institute (NCI) CA263301-01A1Wellcome Trust
Abstract
In solid tumor oncology, circulating tumor DNA (ctDNA) is poised to transform care through accurate assessment of minimal residual disease (MRD) and therapeutic response monitoring. To overcome the sparsity of ctDNA fragments in low tumor fraction (TF) settings and increase MRD sensitivity, we previously leveraged genome-wide mutational integration through plasma whole-genome sequencing (WGS). Here we now introduce MRD-EDGE, a machine-learning-guided WGS ctDNA single-nucleotide variant (SNV) and copy-number variant (CNV) detection platform designed to increase signal enrichment. MRD-EDGE
Indexed as
Circulating Tumor DNADNA Copy Number VariationsMachine LearningNeoplasm, ResidualTumor BurdenBiomarkers, TumorColorectal NeoplasmsHumansLung NeoplasmsNeoplasmsPolymorphism, Single NucleotideWhole Genome SequencingBiomarkers, TumorCirculating Tumor DNA
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.